Join to view full profile
2101 cottontail laneFranklin Center, NJ 08873
Dr. Koneru is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2008 - 2011
Rutgers Robert Wood Johnson Medical SchoolClass of 2008
Certifications & Licensure
NY State Medical License 2011 - 2028
Clinical Trials
- Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant Start of enrollment: 2020 Oct 14
Roles: Study Director, Contact
- Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma Start of enrollment: 2023 Jan 02
Roles: Contact
Publications & Presentations
PubMed
- 53 citationsLong-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.Sundar Jagannath, Thomas G Martin, Yi Lin, Adam D Cohen, Noopur Raje
Journal of Clinical Oncology. 2025-09-01 - 6 citationsReal-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database.Binod Dhakal, Jinghua He, Jordan M Schecter, William Deraedt, Ana Slaughter
Clinical Lymphoma, Myeloma & Leukemia. 2025-06-01 - 39 citationsSafety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid TumorsMark H. O'Hara, Wells A. Messersmith, Hedy L. Kindler, Wei Zhang, Celine Pitou
Journal of Pancreatic Cancer. 2020-03-12
Press Mentions
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual MeetingJune 3rd, 2025- MRKR (Marker Therapeutics, Inc): Something with Huge Risk:RewardJuly 19th, 2021
- Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell TransplantMarch 3rd, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
